In the ENZAMET trial, tissue and blood samples from patients in the randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer (1,200 patients) will be used to identify biomarkers that are prognostic and/or predictive of response to treatment, safety and resistance to study treatment including genomics and metabolic studies.